Microfluidic technologies offer a paradigm shift in healthcare diagnostics and monitoring, with potential implications across a multitude of clinical scenarios. Their optimal implementation hinges on robust, evidence-based clinical guidelines. This study provides an in-depth quality assessment of existing guidelines for microfluidic technologies used to rapidly diagnose COVID-19 utilizing the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument.